Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab + Low-intensity Chemotherapy vs SOC in Older Adults with Newly Diagnosed Ph-negative B-cell Precursor ALL (Golden Gate Study)
NCT04994717Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Nov 2021
- Primary completion
- Sep 2029
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 32
01
Overview
A Phase 3 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Amgen. Started Nov 2021; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04994717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994717.